Articoli anno 1999
Complete
remission of multiple hepatocellular carcinomas associated with hepatitis
C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated
tegafur/uracil
Ishikawa T, Ichida T, Ishimoto Y, Yokoyama J, Nomoto M, Ebe Y,
Usuda H, Naito M, Asakura H Third Department of Internal Medicine, Niigata
University School of Medicine, Niigata City, Japan.
Natural
history of chronic hepatitis C
Canadian Association for the Study of the Liver
Oncolysis
of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent,
genetically engineered herpesvirus
Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA, Tanabe
KK Department of Surgery, Massachusetts General Hospital, Harvard Medical
School, Boston.USA Cancer Res 2000 Jun 1;60(11):2790-5
Interferon
therapy reduces the risk for hepatocellular carcinoma: national surveillance
program of cirrhotic and noncirrhotic patients with chronic hepatitis C in
Japan
IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon
Therapy. Department of Gastroenterology, University of Tokyo, Japan. Ann Intern
Med 1999 Aug 3;131(3):174-81
Effect
of transcatheter arterial chemoembolization on kidney hemodynamics and function
in patients with cirrhosis and hepatocellular carcinoma
Nakano R, Iwao T, Oho
K, Ono N, Sakai T, Sato M, Yamawaki M, Miyamoto Y, Sakai K, Takeda T, Tsuruta
O, Sata M, Toyonaga A. Second Department of Medicine, Kurume University School
of Medicine, Japan. J Hepatol 1999 Aug;31(2):340-6
High
alpha-fetoprotein level in HCV-related nodular liver cell dysplasia
Ng FH, Chow KC, Cheng CS, Kng C, Ng WF, Wong BC. Department of Medicine, Ruttonjee
Hospital, Wan Chai, Hong Kong, China. Am J Gastroenterol 1999 Aug;94(8):2296-7
Increased
Risk of Hepatocellular Carcinoma in Male Hepatitis B Surface Antigen Carriers
With Chronic Hepatitis Who Have Detectable Urinary Aflatoxin Metabolite M1
Zongtang Sun 1, Peixin Lu 2, Mitchell H.
Gail 3, David Pee 4, Qinan Zhang 2, Lihua Ming 1, Jinbing Wang 2, Yan Wu 2,
Guoting Liu 1, Yuying Wu 1, and Yuanrong Zhu 2.
1 Cancer Institute, National Laboratory of Molecular Oncology, Chinese Academy
of Medical Sciences, Beijing, China; 2 Liver Cancer Institute, Jiangsu, China;
3 National Cancer Institute, Division of Cancer Epidemiology and Genetics,
Bethesda MD; and 4 Information Management Services, Rockville, MD. Hepatology,
August 1999, p. 379-383, Vol. 30, No. 2
Should hepatomas be treated with hepatic resection or transplantation? Yamamoto J, Iwatsuki S, Kosuge T, Dvorchik I, Shimada K, Marsh JW, Yamasaki S, Starzl TE Department of Surgery, National Cancer Center Hospital, Tokyo, Japan. Cancer 1999 Oct 1;86(7):1151-8
Use
of interferon for prevention of hepatocellular carcinoma in cirrhotic patients
with hepatitis B or hepatitis C virus infection
Baffis V, Shrier I, Sherker
AH, Szilagyi A. Sir Mortimer B. Davis-Jewish General Hospital and McGill University,
Montreal, Quebec, Canada. Ann Intern Med 1999 Nov 2;131(9):696-701
Cancer
risk in primary biliary cirrhosis: a study in northern England
Howel D, Metcalf JV,
Gray J, Newman WL, Jones DE, James OF. Department of Epidemiology and Public
Health, The Medical School, Newcastle-upon-Tyne, UK. Gut 1999 Nov;45(5):756-60
Intention-to-treat
analysis of surgical treatment for early hepatocellular carcinoma: resection
versus transplantation
Llovet JM, Fuster J,
Bruix J. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS),
Hospital Clinic, University of Barcelona, Catalonia, Spain. Hepatology 1999
Dec;30(6):1434-40
Chi siamo Faq Links Reviews News E-mail Casi clinici Immagini